RZLT
Price
$5.87
Change
-$0.08 (-1.34%)
Updated
Aug 1 closing price
Capitalization
510.67M
38 days until earnings call
SYRE
Price
$16.26
Change
-$0.71 (-4.18%)
Updated
Aug 1 closing price
Capitalization
981.35M
Earnings call today
Interact to see
Advertisement

RZLT vs SYRE

Header iconRZLT vs SYRE Comparison
Open Charts RZLT vs SYREBanner chart's image
Rezolute
Price$5.87
Change-$0.08 (-1.34%)
Volume$909.37K
Capitalization510.67M
Spyre Therapeutics
Price$16.26
Change-$0.71 (-4.18%)
Volume$551.67K
Capitalization981.35M
RZLT vs SYRE Comparison Chart in %
Loading...
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RZLT vs. SYRE commentary
Aug 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RZLT is a Buy and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 04, 2025
Stock price -- (RZLT: $5.87 vs. SYRE: $16.26)
Brand notoriety: RZLT and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RZLT: 79% vs. SYRE: 93%
Market capitalization -- RZLT: $510.67M vs. SYRE: $981.35M
RZLT [@Biotechnology] is valued at $510.67M. SYRE’s [@Biotechnology] market capitalization is $981.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RZLT’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • RZLT’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, RZLT is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RZLT’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • RZLT’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RZLT is a better buy in the short-term than SYRE.

Price Growth

RZLT (@Biotechnology) experienced а -6.83% price change this week, while SYRE (@Biotechnology) price change was -8.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

RZLT is expected to report earnings on Nov 06, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($981M) has a higher market cap than RZLT($511M). RZLT YTD gains are higher at: 19.796 vs. SYRE (-30.155). RZLT has higher annual earnings (EBITDA): -77.12M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. RZLT (86.9M). SYRE has less debt than RZLT: SYRE (0) vs RZLT (1.78M). RZLT (0) and SYRE (0) have equivalent revenues.
RZLTSYRERZLT / SYRE
Capitalization511M981M52%
EBITDA-77.12M-214.36M36%
Gain YTD19.796-30.155-66%
P/E RatioN/A1.72-
Revenue00-
Total Cash86.9M565M15%
Total Debt1.78M0-
FUNDAMENTALS RATINGS
RZLT vs SYRE: Fundamental Ratings
RZLT
SYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3962
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
n/a19

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RZLT's Valuation (53) in the null industry is in the same range as SYRE (74) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to SYRE’s over the last 12 months.

RZLT's Profit vs Risk Rating (97) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to SYRE’s over the last 12 months.

RZLT's SMR Rating (98) in the null industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to SYRE’s over the last 12 months.

RZLT's Price Growth Rating (39) in the null industry is in the same range as SYRE (62) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that SYRE’s stock grew similarly to RZLT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RZLTSYRE
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIKJX16.74-0.08
-0.48%
Fidelity Advisor Real Estate Z
SLCVX29.08-0.28
-0.95%
Saratoga Large Capitalization Value I
PGSYX22.20-0.24
-1.07%
Victory Pioneer Global Equity Y
MITDX37.91-0.59
-1.53%
MFS Massachusetts Investors Tr R4
SFSNX17.28-0.28
-1.59%
Schwab Fundamental US Small Company Idx

RZLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RZLT has been loosely correlated with RLAY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RZLT jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RZLT
1D Price
Change %
RZLT100%
-1.34%
RLAY - RZLT
47%
Loosely correlated
-4.55%
XNCR - RZLT
45%
Loosely correlated
-4.09%
ATYR - RZLT
42%
Loosely correlated
-0.42%
CRNX - RZLT
41%
Loosely correlated
-2.62%
SYRE - RZLT
41%
Loosely correlated
-4.18%
More